Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)


Phase 3 Results

Eligibility Criteria

Inclusion Criteria

Men and women at least 18 years old with evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems by one or more of the following:
- history of myocardial infarction (heart attack)
- history of ischemic stroke (stroke due to a blocked artery)
- history of peripheral arterial disease

Exclusion Criteria

- history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor, or aneurysm
- any bleeding disorder or abnormality
- sustained severe hypertension or valvular heart disease
- current or recent platelet count <100,000 mm^3
- planned or ongoing treatment with a blood thinning medication
- pregnancy
- any significant medical or physiological condition or abnormality that could put the subject at increased risk or limit the subject's ability to participate for the duration of the study